Global Artificial Pancreas Device Systems (APDS) Market Research and Upcoming Forecast Report
© 2019 IMARC All Rights Reserved
Author: Elena Anderson, Marketing Manager | Copyright © IMARC Service Pvt Ltd. All Rights Reserved IMARC Group
About IMARC Group
Report Description
International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and region.The s to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
Report Description and Highlights Report Description Artificial Pancreas Device Systems (APDS) Market Outlook 2026:
According to the latest report by IMARC Group, titled "Artificial Pancreas Device Systems (APDS) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026," the global artificial pancreas device systems (APDS) market reached a value of US$ 1,726 Million in 2020. Artificial pancreas device systems (APDS) refer to a diabetes management system that is designed to regulate blood glucose levels in the human body. These systems mimic the functioning of a healthy pancreas with the help of a continuous glucose monitor (CGM) and an insulin infusion pump. The CGM, along with a sensor that is subcutaneously placed under the patient's skin, is utilized to track blood glucose levels and to determine the required insulin level of the body by evaluating real-time glucose readings. In case insulin deficit is registered by the CGM, the computer-controlled algorithm of the system sends an alert to the infusion pump that delivers the appropriate amount of insulin required by the body throughout the day in controlled amounts. Request for a PDF sample of this report: https:// www.imarcgroup.com/artificial-pancreas-device-systems-market/requestsample
Report Description and Highlights
Report Description
Global Artificial Pancreas Device Systems (APDS) Market Trends:
The global market is primarily driven by the rising prevalence of several lifestyle disorders, such as obesity and diabetes. This is further facilitated by the confluence of numerous factors, including a lack of physical activities and shifting dietary preferences. Consequently, there has been a significant increase in the demand for efficient glucose monitoring solutions, which is providing a thrust to the uptake of APDS. These systems offer flexibility, rapid action and enhanced convenience to the users, which has contributed to their widespread preference among masses. Continual innovations and extensive research and development (R&D) activities have led to the introduction of software-based wireless systems that are equipped with automated controls, which is acting as another major growth-inducing factor. The market is further driven by the development of versatile devices that are integrated with advanced technologies.
Report Description and Highlights
Report Description
For instance, Beta Bionics, a Massachusetts-based company, received breakthrough device designation from the Food and Drug Administration (US FDA) in the United States for developing its iLet Bionics Pancreas System that functions as three medical devices in one: as an insulin-only bionic pancreas, a glucagon-only bionic pancreas or a bihormonal bionic pancreas using insulin and glucagon. The system employs artificial intelligence (AI) and machine learning that aids in understanding the changing insulin needs of the patient. Looking forward, IMARC Group expects the market to grow at a CAGR of 13.1% during 2021-2026.
Report Description and Highlights
Report Description Key Market Segmentation: Breakup by Device Type:
•Threshold Suspend Device Systems •Control-to-Range Systems •Control-to-Target Systems
Breakup by Treatment Type: •Bi-hormonal •Insulin Only •Hybrid
Breakup by End-User: •Hospitals •Medical Centres •Others
Report Description and Highlights
Report Description Breakup by Region:
•North America •Asia Pacific •Europe •Latin America •Middle East and Africa Note: We are updating our research report 2021-2026. If you want to need latest primary and secondary data with Cost Module, Business Strategy, Distribution Channel, etc
Report Description and Highlights
Report Description Competitive Landscape: •Beta Bionics Inc. •Bigfoot Biomedical Inc. •Dexcom Inc. •Inreda Diabetic B.V. •Insulet Corporation •Johnson & Johnson •Medtronic Inc. •Roche Holding AG •Tandem Diabetes Care Inc.
View Report TOC, Figures and Tables: https:// www.imarcgroup.com/artificial-pancreas-device-systems-market
A partial List of
We are the trusted business partners to the
Clients world's leading corporates, governments, and ourPartial ClientsList of institutions
Report Description and Highlights
Report Description
© 2019 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.
A partial List of
We are the trusted business partners to the
of Clients leading corporates, governments, and ourPartial ClientsListworld's institutions
Contact Us
FOR MORE DETAILS Visit us at :
https://www.imarcgroup.com Stay With Us:
TELEPHONE: +1-631-791-1145 E-MAIL: sales@imarcgroup.com